Motexafin gadolinium
- Generic Name
- Motexafin gadolinium
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C52H72GdN5O14
- CAS Number
- 246252-06-2
- Unique Ingredient Identifier
- 0BG5NE3APZ
- Background
Motexafin gadolinium is studied in the treatment of cancer by Pharmacyclics. It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells. It belongs to the family of drugs called metalloporphyrin complexes. Also called gadolinium texaphyrin.
- Indication
Investigated for use/treatment in brain cancer, cancer/tumors (unspecified), lung cancer, and lymphoma (non-hodgkin's).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases
- Conditions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 45
- Registration Number
- NCT00121420
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
- Conditions
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2009-04-03
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 25
- Registration Number
- NCT00120939
- Locations
- ๐บ๐ธ
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- First Posted Date
- 2005-01-05
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 27
- Registration Number
- NCT00100711
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
๐บ๐ธThe Ohio State University, Columbus, Ohio, United States
๐บ๐ธThe Mayo Clinic, Rochester, Minnesota, United States
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
- Conditions
- Interventions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 30
- Registration Number
- NCT00089284
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
๐บ๐ธJesse B. Brown Veterans Affairs Medical Center, Chicago, Illinois, United States
Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery
- Conditions
- First Posted Date
- 2004-08-04
- Last Posted Date
- 2012-11-14
- Target Recruit Count
- 45
- Registration Number
- NCT00003798
- Locations
- ๐บ๐ธ
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-06-23
- Last Posted Date
- 2007-05-15
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 35
- Registration Number
- NCT00086034
Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas
- Conditions
- First Posted Date
- 2004-06-09
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00003410
- Locations
- ๐บ๐ธ
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2004-04-05
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00022256
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Gadolinium Texaphyrin Plus Radiation Therapy in Treating Patients With Supratentorial Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2004-03-08
- Last Posted Date
- 2018-06-27
- Target Recruit Count
- 6
- Registration Number
- NCT00006452
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
- Conditions
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT00003411
- Locations
- ๐บ๐ธ
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
๐บ๐ธUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
๐บ๐ธUniversity of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.